RNA Editing Breakthrough by Wave Life Sciences
Summary: Wave Life Sciences Announces Success in First-Ever Human RNA Editing Clinical Trial, Marking a Critical Milestone in Precision Medicine”
Crescent Biopharma’s Double Win: Reverse Merger NASDAQ Debut and $200M Funding
Summary: GlycoMimetics, following unsuccessful Phase 2/3 clinical trials, accepted the transaction allocating 3.1% equity in the post-merger entity to its shareholders.
Lundbeck Takes Over Longboard Pharmaceuticals in $2.6 Billion Deal
Summary: The acquisition provided Lundbeck with rights to vexicaserin, an investigational therapy targeting 5-HT2C receptors involved in seizure severity modulation.
Roche Extends Gene Therapy Partnership with Dyno… Invests Over $1 Billion in AI-Driven Delivery Tool Design
Summary: After forming a gene therapy partnership with Dyno Therapeutics in 2020, they announced a $50 million upfront payment to design new adeno-associated virus (AAV) vectors as gene therapy delivery tools.
Novartis’ $2.9B MorphoSys bet stumbles as safety delays filing
Summary: Novartis Faces Setback in Acquisition Strategy. Months post-acquisition, the company disclosed safety concerns that may result in multi-year delays for the core asset’s approval submission.
